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ABSTRACT
According to the literature, there have been limited studies describing the efficacy of L-carnitine (LC) administration 
in goats. The present study was designed to evaluate the influence of orally administered LC on some immune-
metabolic variables, as well as the redox status in goats with experimentally induced pregnancy toxemia (PT). The 
study included eighteen clinically healthy Baladi goats at 110 ± 5 days of gestation. The animals were randomly 
allocated into three equally-sized groups: control, toxemic (PT), and toxemic treated with LC (TLC). On day 110 ± 
5 of gestation, the goats in the TLC group received 10 mL of LC given as an oral drench once daily. Administration 
of LC was continued for 20 consecutive days. At day 130 of gestation, PT was experimentally induced in the animals 
of the PT and TLC groups by means of feed withdrawal for 72 hours. For biochemical analyses, blood samples 
were collected from each investigated doe via jugular vein puncture before PT induction (T0), and once daily for 
five consecutive days (T1, T2, T3, T4, and T5). The clinical findings of PT appeared in all the goats of the PT group 
after 72 hours of feed withdrawal, while the goats of the TLC group did not show any clinical symptoms throughout 
the study period. Administration of LC elicited initial and sustained low serum levels of malondialdehyde (MDA), 
tumor necrosis factor (TNF-α), and high serum glucose, superoxide dismutase (SOD) and interleukin (IL)-10 at T0 
compared with those of the control and PT groups. At T3, goats that received LC showed significantly lower values 
of β-hydroxybutyric acid, non-esterified fatty acid, triacylglycerols, MDA, TNF-α, IL-1β, IL-6, and higher values of 
total cholesterol, glutathione peroxidase, SOD, and IL-10 than those of the PT group. Our data suggest that orally 
administered LC could be useful in ameliorating the immune status and improving lipid metabolism in goats with PT.
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Introduction
Pregnancy toxemia (PT) is a metabolic disease 
caused by a negative energy balance occurring 
in pregnant ewes and does, particularly in those 
carrying multiple offspring. The disease occurs 
during the late gestation period (the last 4-6 weeks 
of pregnancy) when about 60% of fetal growth 
takes place (LIMA et al., 2012). During that time, 
approximately 33-36% of blood glucose is directed 
to the fetoplacental unit to satisfy its energy 
demands (LIMA et al., 2012). The increased energy 
required by the fetuses, combined with hormonal 
alterations, has a great impact on the carbohydrate 
and lipid metabolism of pregnant animals, meaning 
that they are in a stressful condition, with the 
likelihood of developing PT (ANDREWS, 1997). 
The natural incidence of PT in intensively farmed 
sheep is approximately 2% of pregnant ewes, but 
the disease may affect the majority of late pregnant 
ewes if there are severe deficiencies in management 
of the disease (RADOSTITS et al., 2007). In a 
study of sheep diseases in Canada, 19% of flocks 
were reported to have PT (DOHOO et al., 1985). 
In Jordanian goats, the overall prevalence of the 
disease has been reported to be 13.3%; while the herd 
prevalence was 87.5% (ISMAIL et al., 2015). The 
major biochemical alterations observed in toxemic 
goats include hyperketonemia, hypoglycemia and 
marked metabolic acidosis (LIMA et al., 2016). 
Accurate and timely diagnosis of the disease 
is crucial to treat the affected animals because 
toxemic goats have high fatality rates, exceeding 
80% in untreated animals, and their condition can 
deteriorate quickly in cases of delayed medical 
treatment (ROOK, 2000; LIMA et al., 2016). 
Hence, disease prevention is important to reduce 
the deleterious consequences of the disease. 
Several effective strategies have been applied 
recently to prevent PT in ewes, including control 
of body condition score in late pregnancy, addition 
of concentrated feed, as well as administration 
of certain drugs (CAL-PEREYRA et al., 2015; 
TEMIZEL et al., 2015). 
Application of L-carnitine (LC), a vitamin-like 
quaternary ammonium compound, synthesized 
endogenously from lysine and methionine in liver 
and kidney (REBOUCHE and ENGEL, 1980), 
holds much promise in a number of disorders in 
humans and laboratory animals but there is a paucity 
of information relating to sheep and goats. There 
has been growing interest in using LC to control 
inflammation in human patients with inflammatory 
bowel disease (MOEINIAN et al., 2013), and those 
suffering from Coronary Artery Disease (LEE et al., 
2015). However, little is still known regarding the 
efficacy of LC for immunity in goats with PT. An 
earlier report found that LC administration could 
protect cell membranes against oxidative damage in 
aging rats (KALAISELVI and PANNEERSELVAM, 
1998). Administration of LC could improve animal 
performance, and could stimulate the physiological 
processes (FATHI and FARAHZODI, 2014). It 
could also act as an antioxidant to protect cell 
membranes against oxidative damages in aging 
rats (KALAISELVI and PANNEERSELVAM, 
1998). Recent studies have shown that LC could 
be effective in several disorders affecting sheep 
(PANCARCI et al., 2007; CITIL et al., 2009) and 
goats during the transition period (KACAR et al., 
2010), and in growing sheep fed diets containing 
non-protein nitrogen (CHAPA et al., 2001). 
However, the influence of orally administered LC 
in goats with PT has not been fully addressed. 
Therefore, the present study was performed to 
evaluate the influence of orally administered LC 
on some immune-metabolic variables, as well as 
the redox status in goats with experimental PT. We 
hypothesized that administration of LC could help 
potentiate immune-metabolic status and influence 
the antioxidant activity in goats with PT.
Materials and methods
Animals. The present study included eighteen, 
clinically healthy, multiparous Baladi goats, at 
3-5 years of age and 35-40 kg body weight, with 
a body condition score of 3-3.5 (on a scale of 
1-5). The study was carried out at the Veterinary 
Teaching Hospital, Faculty of Veterinary Medicine, 
Mansoura University, during the period between 
March to May 2015. All procedures were 
performed in accordance with the Guidelines 
for the Care and Use of Agricultural Animals in 
Research and Teaching, 3rd ed. (http://www.fass.
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org/), and those of Mansoura University Animal 
Care. Procedures were approved by the Ethical 
Committee of Mansoura University. Animals 
were subjected to thorough clinical examinations 
before and throughout the experimental period. 
The gestation time and the number of fetuses were 
determined ultrasonographically using a 5MHz 
trans-abdominal probe (CUS2000, Carewell, 
China). The investigated animals were at 110 ± 
5 days of gestation (means ± SD), and each doe 
carried at least two fetuses. The animals were kept 
in separated pens, under the same environmental 
conditions, and were fed 250 g concentrate/head/
day, consisting of a mixture of ground yellow corn, 
wheat bran, and cotton seed meal, while berseem 
hay and water were offered ad libitum. 
Study design and allocation of animals. The 
animals were randomly allocated into three equally-
sized groups (of six goats each) as follows: control, 
toxemic (PT), and toxemic treated with LC (TLC). 
On day 110 ± 5 of gestation (means ± SD), LC 
(Carnivit 50 mg/mL, Vetsintez" LLC, Ukraine) was 
given as an oral drench to goats in the TLC group, 
at a dose of 500 mg active ingredient/head/day, 
according to a method previously described (CITIL 
et al., 2009). LC administration continued for 20 
consecutive days. At day 130 of gestation, PT was 
induced in animals of the PT and TLC groups by 
means of feed withdrawal for 72 hours, with free 
access to water. Food was offered to the animals 
once clinical signs of PT appeared. All the animals 
were kept under complete supervision and were 
thoroughly monitored throughout the experiment. 
The investigated animals were clinically examined 
by three independent clinicians. Particular emphasis 
was laid on recording vital signs, including rectal 
temperature, heart rate, respiratory rate, and visible 
mucous membrane color, besides observing the 
potential alterations in general demeanor, eyesight 
and rumen motility. 
Sampling. Blood samples were collected for 
biochemical analyses from each investigated doe 
by jugular vein puncture at 9.00 A.M before the 
morning meal and before induction of PT (T0; i.e. 
at the day 129), and once daily for five consecutive 
days (T1, T2, T3, T4, and T5). 
The blood samples were collected into tubes 
without anticoagulant for serum separation. Only 
clear non-hemolyzed serum was collected and kept 
frozen at -20 0C for further biochemical analysis 
of glucose, β-hydroxy butyric acid (BHBA), non-
esterified fatty acid (NEFA), total cholesterol, 
triacylglycerols, malondialdehyde (MDA), 
glutathione peroxidase (GSH-Px), superoxide 
dismutase (SOD), tumor necrosis factor (TNF)-α, 
interleukin (IL)-1β, IL-6 and IL-10. The following 
commercial kits were used for quantifying the values 
of the different serum variables according to the 
suppliers’ standard protocols: glucose (Spinreact, 
Spain), BHBA (Biochemical Enterprise), total 
cholesterol (Spinreact, Spain), triacylglycerols 
(Spinreact, Spain), MDA (Northwest Life Science 
Specialist, LLC), GSH-Px, and SOD (Cayman 
Chemical Company, USA). NEFA were analyzed 
according to a chemical method previously 
described by SCHUSTER (1979). 
Concentrations of circulating cytokines were 
determined in undiluted serum by using goat 
specific ELISA kits, according to the instructions 
supplied by the manufacturer. The plates were read 
at 450nm and a reference wavelength of 550 nm, 
using an automated microplate ELISA reader (Bio 
TEC, ELX800G; USA). Values were expressed as 
pg/mL. Samples were run in duplicate for all the 
cytokines tested. The test kits used for estimating 
the respective cytokines were as follows: TNF-α 
(Cloud-Clone Corp, USA), IL-1β (Genorise 
Scientific, INC., USA), IL-6 (Cloud- Clone Corp, 
USA) and IL-10 (Genorise Scientific, INC, USA). 
Statistical analysis. Data analyses were 
performed using a statistical program (SPSS, 
version 15. USA). As the data were normally 
distributed using the Shapiro-Wilk normality test, 
the mean values and standard deviation for each 
variable at each time point were presented. A two-
way repeated measure ANOVA with the Bonferroni 
post hoc test was performed to assess the effect of 
treatment, time, and time × treatment interaction 
on the tested variables. Differences at P<0.05 were 
considered statistically significant. 
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Results
The clinical signs of the disease appeared in 
all goats of the PT group after 72 hours of feed 
withdrawal. The clinical symptoms observed 
were teeth grinding (4 out of 6), sternal recumbent 
posture (1 out of 6), while muscular tremors, rumen 
hypomotility and disinclination to move were all 
detected in goats of the PT group. The vital signs, 
including heart rate and respiratory rate, were 
significantly (P<0.05) higher in the PT group than 
those of the TLC group (Table 1); however, the 
rectal temperature was not significantly (P>0.05) 
different between the three groups. All clinical 
symptoms abated once feed was offered. None of 
the animals in the TLC group showed any signs of 
toxemia and were clinically healthy throughout the 
study period.
Table 1. Means ± SD of some clinical variables in goats 
with pregnancy toxemia (PT-group), L-carnitin treated 





















Heart rate  
(beats/min) 80
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a, b Variables with different superscript within the same row are 
significantly different at P<0.05 
The treatment affected glucose concentration 
(P<0.0001), which was greater in the TLC group 
than the PT and control groups. Time also affected 
glucose concentration (P<0.0001) which was 
greater in the TLC group at T0 and T1 than in the 
other groups. There was also a significant effect from 
the interaction of time and treatment (P<0.0001), 
as glucose levels did not change over time in the 
control group, whereas in the PT and TLC groups 
they declined from T0 to T3, and then rose to the 
level of the control group (Fig. 1). In general, the 
TLC group had greater concentrations of glucose 
than the PT group throughout the observation 
period. 
Fig. 1. The time course (mean ± SD) of serum glucose 
concentration (mmol/L) in goats with pregnancy 
toxemia (PT-group) and the L-carnitine-supplemented 
group (TLC group) compared with the control. Effect 
of treatment (F = 302.06; P<0.0001), effect of time 
(F = 55.44; P<0.0001) and the interaction of time and 
treatment (F = 20.65; P = 0.0001). 
Concentrations of BHBA, NEFA, and 
triacylglycerols were significantly affected by 
treatment and time (P<0.0001), and were higher in 
the PT group at T2 to T3 (for BHBA), T1 to T4 
(for NEFA), and T3 to (T4 for triacylglycerols) than 
those of the other groups, and then declined to the 
levels of the control group (Fig. 2A, 2B, 2D). There 
was also a significant effect from the interaction of 
time and treatment (P<0.0001) as these variables did 
not change over time in the control group. On the 
other hand, concentrations of total cholesterol were 
significantly affected by treatment (P<0.0001) and 
time (P<0.0001), being lower in the PT group at T3 
than in the other groups, but they then rebounded to 
the level of the control group. The interaction also 
affected cholesterol concentration (P<0.0001) as its 
level did not change over time in the control group 
(Fig. 2C). 
M. R. El-Ashker et al.: L-carnitine supplementation in goat with pregnancy toxemia
Vet. arhiv 90 (4), 365-375, 2020 369
The treatment affected MDA concentrations 
(P<0.0001), which were lower in the TLC group 
than the PT and control groups. Time also affected 
MDA concentration (P<0.007), which was lower in 
the TLC group from T0, T1 to T2 than in the other 
groups. The interaction of time and treatment also 
affected its concentrations (P = 0.021), whereas in 
the PT group, its levels peaked at T3 then declined 
from T4 to the level of the control group (Fig. 3A). 
Concentrations of SOD were affected by treatment 
(P<0.0001), and time (P<0.0001), and were higher 
in the TLC group at T0 than in the other groups. 
The interaction of time and treatment also 
affected its concentrations (P = 0.0001). Its level 
declined in the PT group from T2, T3 to T4, then 
gradually recovered to the level of the control 
group (Fig. 3B). Levels of GSH-Px were affected 
by treatment (P<0.0001), and time (P<0.0002), 
and were lower at T3 in the PT and TLC groups 
compared with the control, then gradually recovered 
to the level of the control group. The interaction of 
time and treatment also affected its concentration 
(P = 0.0001), as GSH-Px levels did not change over 
time in the control group (Fig. 3C).
Fig. 2. Time course (means ± SD) of serum β-hydroxy butyrate (mmol/L) [A], non-esterified fatty acids (mmol/L) 
[B], total cholesterol (mmol/L) [C] and triacylglycerols concentrations (mmol/L) [D] in goats with pregnancy 
toxemia (PT-group) and L-carnitine-supplemented group (TLC group) compared with the control. For BHBA: effect 
of treatment (F = 72.52; P<0.0001), effect of time (F = 21.23; P<0.0001) and interaction between time and treatment 
(F = 16.73; P = 0.0001). For NEFA: effect of treatment (F = 17.51; P<0.0001), effect of time (F = 18; P = P<0.0001) 
and interaction between time and treatment (F = 80.02; P<0.0001). For cholesterol: effect of treatment (F = 41.29; 
P<0.0001), effect of time (F = 9.83; P<0.0001) and interaction between time and treatment (F = 3.59; P = 0.0005).
For triacylglycerols: effect of treatment (F = 82.83; P<0.000), effect of time (F = 8.67; P<0.0001) and interaction 
between time and treatment (F = 4.34; P<0.0001).
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Fig. 3. Time course (means ± SD) of malondialdehyde levels (µmol/L) [A], glutathione peroxidase activity (IU/L) 
[B], superoxide dismutase activity (U/L) [C] in goats with pregnancy toxemia (PT-group) and the L-carnitine 
supplemented group (TLC group) compared with the control. For MDA: effect of treatment (F = 56.60; F = 2.51; 
P<0.0001), effect of time (F = 3.76; P<0.007) and interaction between time and treatment (F = 2.51; P = 0.021). For 
GSH-Px, effect of treatment (F = 22.71; P<0.0001), effect of time (F = 5.39; P<0.0002) and interaction between time 
and treatment (F = 1.92; P = 0.052). For SOD: effect of treatment (F = 71.41; P<0.0001), effect of time (F = 13.12; 
P<0.0001) and interaction between time and treatment (F = 5.76; P = 0.0001).
The serum concentrations of TNF-α were 
affected by time (P<0.0002), and treatment 
(P<0.0001), and were lower in the TLC group at T0 
than in the PT and control groups. The interaction 
of time and treatment also affected its concentration 
(P = 0.0001) as its levels did not change over time 
in the control group. In the PT group, the levels of 
TNF-α rose from T3 to T4 then declined to the level 
of the control group. 
On the other hand, the treatment affected levels 
of IL-1β (P<0.0017), IL-6 (P<0.0038) and IL-10 
(P<0.0001), which were higher (for IL-1β and IL-
6) and lower (for IL-10) in the PT group than those 
of other groups, while their levels were not affected 
either by time (P = 0.056, P = 0.757, P = 0.0771), or 
the interaction of time and treatment (P = 0.106, P = 
0.543, P = 0.187) (Fig. 4A-D).
3A 3B
3C
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Discussion
Our data clearly suggest that orally administered 
LC could be useful in ameliorating both immune 
response and lipid metabolism in goats with PT. It 
is worth mentioning that the goats in the TLC group 
did not exhibit any clinical signs, and remained 
clinically sound with normal vital signs throughout 
the experiment. These results are promising and 
would suggest the potentially ameliorative role of 
LC in goats with PT. Nevertheless, toxemic goats (PT 
group) exhibited variable clinical symptoms after 
72 hours of feed withdrawal which were in harmony 
with those described by GONZALEZ et al. (2011). 
The clinical signs observed could be linked to the 
hypoglycemia and/or hyperketonemia associated 
with experimental PT (RADOSTITS et al. 2007). 
A marked drop in serum glucose concentration 
was detected in the PT group, particularly at T3, 
compared with those of the TLC group, and the 
values were somewhat restored after feed supply. 
These findings were in agreement with those 
found by ALBAY et al. (2014), and were attributed 
to starvation and the increased requirements 
of the developing fetuses (ANDREWS, 1997). 
Fig. 4. Time course (means ± SD) of tumor necrosis factor-α levels (pg/mL) [A], IL-1β levels (pg/mL) [B], 
interleukin-6 levels (pg/mL) [C] and interleukin-10 levels (pg/mL) [D] in goats with pregnancy toxemia (PT-group) 
and the L-carnitine supplemented group (TLC group) compared with the control. For TNF-α: effect of treatment 
(F = 20.06; P<0.0001), effect of time (F = 5.44; P<0.0002) and interaction between time and treatment (F = 4.91; P 
= 0.0001). For IL-1β: effect of treatment (F = 7.63; P<0.0017), effect of time (F = 2.40; P = 0.056) and interaction 
between time and treatment (F = 1.75, P = 0.1069). For IL-6: effect of treatment (F = 5.93; P<0.0038), effect of time 
(F = 0.52; P = 0.757) and interaction (F = 0.89; P = 0.543). For IL-10, effect of treatment (F = 17.51; P<0.0001), 
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A high ketone body concentration could also 
impair the endogenous production of glucose, 
which in turn exacerbates the development of PT 
(SCHLUMBOHM and HARMEYER, 2004). 
Goats that received LC exhibited initial and 
sustained hyperglycemia at T0 compared with the 
other groups. The improved glycemia in the TLC 
group has also been documented in previous reports 
(CHAPA et al., 2001 and KACAR et al., 2010) and 
is probably attributed to the role of LC as a co-
factor for transporting long-chain fatty acids into 
the mitochondria, in order to produce energy in the 
peripheral tissues (HOPPEL, 2003). It has also been 
found that parenteral administration of LC in Halep 
(Damscus) goats can lead to continuous elevation 
of serum glucose levels in the 2nd and 3rd weeks prior 
to parturition (KACAR et al., 2010). Other reports 
have confirmed the same effect of LC in growing 
lambs (CHAPA et al., 2001). Administration of LC 
has been suggested to improve glucose status in 
dairy cattle by decreasing liver lipid accumulation, 
and stimulating hepatic glucose output, which 
diminish the risk for developing metabolic disorders 
during the early lactation period (CARLSON et 
al., 2007). In contrast, parenteral administration of 
LC to fat tailed ewes did not affect serum glucose 
levels during the transition period (PANCARCI et 
al., 2007). 
Serum values of BHBA, NEFA, and 
triacylglycerols rose progressively in the PT group 
at various time points, with maximum alterations 
recorded at T3, while serum values of total 
cholesterol were significantly altered at the same 
time point, but in an inverse manner. These findings 
are in line with previous reports (SCHLUMBOHM 
and HARMEYER, 2004; GONZALEZ et al., 
2011; LIMA et al., 2012; ALBAY et al., 2014). 
The resulting hyperketonemia and the alterations 
in lipid profile could be attributed to starvation 
and increased lipolysis in the adipose tissue due 
to hypoglycemia and the liberation of long chain 
fatty acids that form ketone bodies in the liver. 
Interestingly, administration of LC provoked a 
positive effect on the metabolic variables tested, in 
the form of lowering serum values of BHBA NEFA, 
and triacylglycerols, and elevating total cholesterol, 
particularly at T3. These results were in agreement 
with those reported in sheep and goats (CITIL et al., 
2009; KACAR et al., 2010), and were attributed to 
the role of LC in β-oxidation of fatty acids, or its 
antioxidant properties. 
Our data show that the goats in the PT group 
had high serum values of oxidative stress marker 
MDA, with low antioxidant activities, particularly 
at T3. These findings clearly demonstrate a state of 
oxidative stress and were in line with those reported 
by GURDOGAN et al. (2014). In a previous study, 
it was thought that elevated values of BHBA could 
up-regulate MDA, and down-regulate antioxidant 
parameters in cattle hepatocytes (SHI et al., 2014). 
Nevertheless, the mechanism of how BHBA 
induces oxidative stress in cattle hepatocytes is 
still unknown. Interestingly, administration of 
LC provoked an initial and sustained decrease 
in circulating MDA, and enhanced the activities 
of antioxidant enzymes, including SOD and 
GSH-Px. These findings could highlight the 
potential importance of LC as an antioxidant for 
protection of the cell membrane against oxidative 
damages. A similar antioxidant role of LC was 
previously suggested in rats (KALAISELVI and 
PANNEERSELVAM, 1998). The efficacy of LC 
in combating oxidative injury could be attributed 
to the inhibition of free radical dissemination, and 
its role in the repair of the oxidized membrane 
phospholipids (DERIN et al., 2004). Moreover, the 
antioxidant role of LC could also be linked either to 
its ability to chelate free Fe2+ ions, with a subsequent 
reduction in free radical generation, or its capability 
to stimulate ATP production, thereby improving the 
overall activity of antioxidant enzymes in the cell 
(LEE et al., 2015). 
Although the etiopathology of PT is not 
precisely known, some evidence has suggested that 
insufficiency of the uterine spiral arteries in perfusion 
of the placenta could likely contribute to causing 
the disease (ROBERTS et al., 1989). Hypoxia, 
due to reduced blood perfusion, could also induce 
placental production of inflammatory cytokines, 
including IL-1α and TNF-α (BENYO et al., 1997). 
These cytokines can be produced either locally or 
originate from the circulation, and can influence 
maternal-placental immune interaction, trophoblast 
invasion and differentiation, and the metabolic 
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and endocrine regulation of the placenta (YARIM 
et al., 2007). Recently, it was demonstrated that 
cytokines (eg. IL-2, interferon-gamma, and TNF-β) 
are customarily harmful to a successful pregnancy 
and can induce cell-mediated cytotoxicity, as well 
as inflammatory responses, while IL-4, IL-5, IL-6, 
and IL-10 are beneficial for humoral response, have 
a pivotal role in a successful pregnancy, and are 
able to induce antibody production, and improve 
mast cell and eosinophil granulocyte differentiation 
(ZHANG et a., 2019). Our data clearly confirm 
that goats in the PT group had high values of 
circulating pro-inflammatory cytokines, including 
TNF-α, IL-6 and IL-1β, which suggests an ongoing 
inflammatory cascade. These findings were in part 
similar to those presented by YARIM et al. (2007) 
and ALBAY et al. (2014) in ewes and goats with 
naturally occurring PT. In the earlier study, the 
authors demonstrated higher levels of circulating 
TNF-α, IL-1β, and monocyte chemotactic protein 
1 in the diseased ewes than in the control, and the 
severity of the disease was worse when the values of 
these cytokines were high. However, the authors of 
the later study stated that PT in goats was associated 
with a sharp increase in serum TNF-α level that was 
higher in clinical cases than sub-clinical ones. In 
a recent study, it was suggested that BHBA can 
enhance production of proinflammatory cytokines 
in cattle hepatocytes, through activation of nuclear 
factor kappa B (NF-κB) and upregulating oxidative 
stress markers, such as MDA and nitric oxide (SHI 
et al., 2014). The authors added that the activated 
nuclear factor kappa B (NF-κB) could induce 
hepatocyte injury by translocating to the nucleus and 
increasing the DNA binding activity to propagate 
the transcription of TNF-α, IL-6 and IL-1β. Along 
the same lines, in an earlier study being conducted 
on women with PT (SARGENT et al., 2003), it was 
shown that these patients demonstrated excessive 
systemic inflammation and increased production 
of inflammatory cytokines. The authors attributed 
these alterations to defects of trophoblast cells, and 
to the destruction of placental debris. 
Our data showed that LC elicited a noticeable 
anti-inflammatory effect by restoring the observed 
alterations in the circulating pro-inflammatory 
cytokines (TNF-α, IL-6 and IL-1β), and enhancing 
the production of anti-inflammatory marker IL-10. 
To the best of our knowledge, this is the first study 
to examine the anti-inflammatory effect of LC in 
goats with PT. Similar findings were observed in 
human studies. For example, administration of LC 
at a dose of 20 mg/kg has also been reported to 
reduce the level of C reactive protein in patients on 
hemodialysis (DURANAY et al., 2006), and control 
inflammation in human patients with inflammatory 
bowel disease (MOEINIAN et al., 2013). A 
higher dose of LC (i.e. 5000 mg twice daily) could 
significantly reduce inflammatory status in patients 
suffering from Coronary Artery Disease. 
Conclusion
Administration of LC has a potential impact on 
disease progression, helps mitigate the appearance 
of clinical signs, and improves glycaemia. It also 
has potentially ameliorative antioxidant and anti-
inflammatory effects. The information provided in 
the present study could encourage the advancement 
of future research in animal welfare and production. 
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Sažetak
Prema podacima iz literature postoji ograničen broj istraživanja primjene L-karnitina (LK) u koza. Cilj ovog 
rada bio je procijeniti učinak oralno primijenjenog LK-a na određene imuno-metaboličke pokazatelje i redoksni 
status u koza u kojih je eksperimentalno izazvana gravidnosna tokesmija (GT). Istraživanje je uključilo 18 klinički 
zdravih koza baladi pasmine čija je gravidnost iznosila 110 ± 5 dana. Životinje su nasumično podijeljene u tri jednake 
skupine: kontrolnu, toksemijsku (GT) i toksemijsku kojoj je davan LK (TLK). Koze u skupini TLK su od 110. ± 5 
dana gravidnosti jedanput dnevno dobivale 10 mL LK-a oralnom drenčer špricom. Primjena LK-a nastavljena je 
sljedećih dvadeset dana uzastopno. Na 130. dan gravidnosti GT je eksperimentalno izazvan u skupinama GT i TLK, 
uz uskraćivanje hrane tijekom 72 sata. U svake je koze iz jugularne vene uzeta krv za biokemijsku analizu prije 
izazivanja GT-a (T0) i jedanput dnevno sljedećih pet dana (T1, T2, T3, T4 i T5). Klinički je GT ustanovljen u svih 
koza u skupini GT 72 sata nakon što im je uskraćena hrana, dok koze iz skupine TLK nisu pokazale kliničke simptome 
za vrijeme istraživanja. Primjena LK-a prouzročila je niske serumske vrijednosti malondialdehida (MDA), faktora 
tumorske nekroze (TNF-α) i visoke serumske vrijednosti glukoze, superoksidne dismutaze (SOD) i interleukina (IL)-
10 prije izazivanja GT-a (T0) u usporedbi s kontrolnom i GT skupinom. Treći dan (T3) koze koje su primile LK 
pokazale su znakovito niže vrijednosti β-hidroksimaslačne kiseline, neesterificirane masne kiseline, triacilglicerola, 
MDA-a, TNF-α, IL-1β, IL-6 te veće vrijednosti ukupnog kolesterola, glutation-peroksidaze, SOD-a i IL-10 od onih 
u skupini GT. Rezultati su pokazali da bi oralno primijenjen LK mogao pridonijeti poboljšanju imunosnog statusa i 
metabolizma masnoća u koza s GT-om.
ključne riječi: gravidnosna toksemija; L-karnitin; citokin; oksidacijski stres _____________________________________________________________________________________________

